Our Portfolio

Investment activity

Selective investment into high conviction opportunities







6 months ended 31 July 2019

In the current market environment, we continue to be highly selective in our investment approach with a focus on high quality, defensive businesses. We invested a total of £64m in the six months with high conviction investments accounting for 38%, including two new co-investments: DOC Generici and RegEd. The ICG network accounted for 31% of new investments.

  • DOC Generici is a leading independent generic pharmaceutical company in Italy. It is active in the supply of drugs for the treatment of all the common medical conditions with a strong presence in areas including cardiovascular, gastrointestinal, metabolism and neurological treatments. We co-invested £10m alongside ICG and a further £1m will be invested through ICG Europe VII. DOC Generici is the third largest company in the Italian pharmaceutical market, which is a resilient and relatively predictable market.
  • RegEd is a leading provider of regulatory compliance software services, primarily to broker-dealers, insurance companies and banks in the United States. The company’s customers include over 200 blue-chip customers including 80% of the top 25 financial services firms in the US. We invested £5m in RegEd alongside a new US manager, Gryphon Investors, including through their fund. We expect RegEd to benefit from a number of favourable trends as its clients transition towards greater automation and less reliance on manual processes.

Both of these businesses have defensive business models, with demonstrated resilience to economic cycles and high cash flow conversion, as well as strong growth drivers and clear value creation plans. Additionally, DOC Generici features a combination of subordinated debt and equity investments giving an element of structural downside protection, a consistent feature of many of our investments with ICG.

Eight new commitments to both existing and new manager relationships

During the period, we completed eight fund commitments, including a new ICG managed fund, resulting in a total of £118m of new fund commitments in the six months. Of the seven third party fund commitments, two are new managers to the Portfolio (AEA and Gryphon), with the remainder to funds raised by managers we have backed successfully before. Of these, two are European funds (IK and Cinven), two are global funds (Advent and Permira), and one is a US fund (Oak Hill). The managers we back tend to raise funds that are oversubscribed and therefore difficult to access, and the calibre of these managers speaks to the relationships that we have built with these firms, in most cases over many years.

Two new relationships are both US-based:

  • AEA is one of the longest established US private firms, having been founded in 1968. It is a highly regarded mid-market manager which we have been tracking for over five years. It focuses on businesses in the industrial and consumer sectors, targeting niche sub-sectors such as packaging and high growth consumer brands. It has a highly operationally focused approach which allows AEA to execute complex transactions successfully such as corporate carve-outs. The investment team which will deploy AEA VII has a successful track record of delivering consistently strong returns through economic cycles.
  • Gryphon Investors is another long-established US manager based in San Francisco, focused on business services, consumer, healthcare and industrial growth. We invested in its fifth fund, which by the time of its final close was already over half committed. This allows us to diligence the underlying investments, as well as to deploy committed capital more efficiently. Gryphon has a highly focused, thematic origination approach which seeks to identify companies within tightly defined sub-sectors which have characteristics aligned with our defensive growth focus. Shortly after committing to the fund, we co-invested in a Gryphon V investment, RegEd which is discussed above.

We also made a €20m commitment to ICG Europe Mid-Market, ICG’s latest European fund. This strategy invests in subordinated debt and equity across a variety of European opportunities, typically with ICG as the sole institutional investor alongside a strong management team. The fund will follow the same successful strategy of ICG Europe, but with a focus on smaller mid-market companies. The fund targets a gross IRR of 18% and a multiple of cost of 1.8x with a focus on low downside risk.

The first half of the year has been highly active from a new commitment perspective, as a significant number of our preferred managers were raising funds in this period. We expect to complete materially fewer new funds in the second half.

Share price (ICGT)

4.00P (0.41%)
8:27AM 16 Dec 2019
The share price information is delayed by at least 15 minutes

Net Asset Value

As of 31 July 2019
Next update: January 2020 – Q3 results
Year Net assets NAV per share Share price Dividends per share
Jan 2019 £731m 1,057p 822p 22p
Jan 2018 £664m 959p 818p 21p
Jan 2017 £613m 871p 698p 20p
Jan 2016 £521m 731p 545p 11p
Jan 2015 £507m 695p 575p 15.5p
Jan 2014 £494m 677p 563p 15.5p
Jan 2013 £460m 631p 487p 5p
Jan 2012 £415m 569p 357p 5p
Jan 2011 £389m 534p 308p 2.25p
Dec 2009 £338m 464p 305p 2.25p
Dec 2008 £327m 449p 187p 4.5p


The information contained herein and on the pages that follow does not constitute an offer to sell, or the solicitation of an offer to acquire or subscribe for, any securities in any jurisdiction where such an offer or solicitation is unlawful or would impose any unfulfilled registration, qualification, publication or approval requirements on ICG Enterprise Trust PLC (the "Company") or its affiliates or agents. Equity securities in the Company have not been and will not be registered under the applicable securities laws of the United States, Australia, Canada, Japan or South Africa (each an “Excluded Jurisdiction”). The equity securities in the Company referred to herein and on the pages that follow may not be offered or sold within an Excluded Jurisdiction, or to any U.S. person ("U.S. Person") as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or to any national, resident or citizen of an Excluded Jurisdiction.

The promotion of the Company and the distribution of this website and the materials contained by it in the United Kingdom are restricted by law. Accordingly, this website and any materials contained by it should only be accessed by, and are directed only at:
(i) persons outside the United Kingdom to whom it is lawful to communicate to; or
(ii) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”); or
(iii) high net worth companies, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order, provided that in each case the website and any materials in are only directed at persons who are "qualified investors" as defined in article 2(1)(e) of Directive 2003/71/EC (as amended) (the "Prospectus Directive") ("Relevant Persons"). Accordingly, this website does not constitute, and does not contain the information required to be contained in, a prospectus as required under the Prospectus Directive.

This website is communicated by ICG Alternative Investment Limited (“ICG AIL”), which is authorised and regulated by the UK Financial Conduct Authority. In communicating this website ICG AIL is acting for the Company and is not responsible for advising persons viewing this website or any other person, or for providing them with the protections which would be given to those who are clients of ICG AIL under the rules of the FCA.
The information on the pages that follow may contain forward looking statements. Any statement other than a statement of historical fact is a forward looking statement. Actual results may differ materially from those expressed or implied by any forward looking statement. The Company does not undertake any obligation to update or revise any forward looking statements. You should not place undue reliance on any forward looking statement, which speaks only as of the date of its issuance.

Your access to this website is governed by the above terms. The Company may change these terms. The changes will be posted on the website. Your access to this website is governed by the version of these terms then in force.

By clicking "I understand and agree" below, you represent, warrant and agree that you (1) have read and understood these terms and the other information set out above, (2) agree to be bound by the terms, (3) do not have a registered address in, and are not resident or located in, an Excluded Jurisdiction (or, if you do, you will not seek to make any investment in the securities of the Company), (4) are not a U.S. Person or a national, resident or citizen of an Excluded Jurisdiction (or, if you are, you will not seek to make any investment in the securities of the Company), (5) are permitted under applicable laws and regulations to receive the information contained in the pages that follow, and (6) agree that you will not transmit or otherwise send any information contained in this website to any person in the United States or to any U.S. Person for the purpose of that person considering an investment in the securities of the Company, or to any publication with a general circulation in the United States.
If you cannot so certify and agree, you must click the button labelled "I decline" or otherwise exit this website.